Short answer
Personalis, Inc. (PSNL) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $22M (up 30.0% year over year) with net income of −$32M.
Q2 2026 key financials · XBRL
- Revenue
- $22M
- +30.0% YoY · +44.5% QoQ
- Net income
- −$32M
- −58.0% YoY · −5.5% QoQ
- Operating margin
- -150.2%
- EPS (diluted)
- −$0.30
- −30.4% YoY · −3.4% QoQ
Source: XBRL data from the Personalis, Inc. (PSNL) Q2 2026 10-Q on SEC EDGAR. USD.
Personalis, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Tempus merger agreement announced July 20, 2026, subject to closing conditions
- Near-term focus on oncology testing, reimbursement coverage, and scaling sequencing capacity beyond 350 trillion bases weekly
Risk Factors
- Merger completion risk triggered by pending Tempus acquisition and unresolved shareholder, Nasdaq, Form S-4, HSR, tax, and adverse-effect conditions
- Transaction valuation risk from Tempus Class A stock fluctuations, potentially reducing consideration below $16.25 per share
- Regulatory risk from required HSR Act waiting-period expiration or termination before merger closing
- Operational disruption risk from merger restrictions limiting capital projects and attractive business opportunities
- Financial risk from significant merger-related professional expenses without benefit if the transaction fails
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Personalis, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.